Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GRI, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Active Comparator: 6.0mg GRI-0621 | Chronic Liver Disease | Phase 2 · NCT02949375 | Terminated |
Also used in these trials (approved or third-party drugs, not GRI's own candidates): Tazarotene.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GRI holds $10.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 12.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRI files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →